RJRoya Raeisi Jaski

Roya Raeisi Jaski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roya Raeisi Jaski has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • From hyperandrogenism to tumorigenesis; a mechanistic perspective on cancer development in PCOS-affected women

    by Zahed Karimi, Sara Abutalebi Nasrabad, Reza Farzaneh, Seyed Amir Banikarim, Farkhondeh Sameipoor, Faezeh Khajeh, Faezeh Nesaei, Roya Raeisi Jaski, Maryam Samadi, Naeem Nikpour

    The mechanistic sequence from hyperandrogenism to tumorigenesis in women with polycystic ovary syndrome (PCOS) encompasses a constellation of structural and functional aberrations spanning the endocrine, metabolic, immunologic, and genetic domains. Chronic hyperandrogenism incites an interconnected cascade through chronic anovulation and unopposed estrogen action, insulin resistance with hyperinsulinemia, low-grade systemic inflammation, oxidative stress, and gut dysbiosis, each playing a synergistic role in promoting oncogenesis. It has been demonstrated that, this syndrome is most strongly associated with an increased risk of endometrial cancer, with a more modest and less consistent association with ovarian and breast cancers. Thyroid cancer risk may also be elevated, particularly in younger women. The underlying mechanisms involve hormonal imbalances, metabolic dysfunction, chronic inflammation, and genetic predisposition. Women with PCOS should be monitored for early signs of these cancers, and management should focus on mitigating risk factors such as obesity, insulin resistance, and chronic anovulation.

  • Open Access

    Prevalence and causes of gynecological surgery cancellations at Shariati Bandar Abbas hospital

    by Banafsheh Tehranineshat, Nasim Zaman Samghabadi, Zahra Shahryarpanah, Zahra Eydizadeh, Roya Raeisi Jaski, Zahra Ziaadini, Farzaneh Barkhordari Ahmadi, Majid Vatankhah, Jahanbakhsh Vahdatnejad, Hossein Mardanparvar, et al.

    Introduction: Surgery cancellation causes complications such as disrupting the daily schedule of surgery in the operating room, delays in patient care, and potential financial losses for the hospital or surgical center. Objectives: This study aimed to investigate the prevalence and causes of gynecological surgery cancellations at Shariati Bandar Abbas hospital. Patients and Methods: This descriptive-analytical study was conducted on 212 patients in the Shariati hospital of Bandar Abbas, Iran, from April to November 2023. Data were collected through a demographic questionnaire and a researcher-made checklist, including clinical data. To analyze data SPSS version 27 and analytical tests were used. Results: Out of 212 studied patients, the surgery for 67 was canceled, resulting in a surgery canceling prevalence rate of 31.6%. Surgery type, age, history of diabetes mellitus, thyroid disease, and other diseases were not risk factors for surgery cancelation (P>0.05); however, cardiovascular disease history, not being nil per os (NPO), and not having surgery consent were independent risk factors (P<0.05). Conclusion: In conclusion, the high prevalence of surgery cancellations in Iran’s educational hospitals necessitates a comprehensive and systematic investigation of the factors involved, including patient evaluation, anesthesiologist approval, patient readiness, and the impact on patients’ overall health and well-being.

  • Open Access

    Investigating the association between the administration of SGLT-2 inhibitors and the risk of urinary tract infection; a systematic review and meta-analysis

    by Ramin Haghighi, Nasim Zaman Samghabadi, Roya Raeisi Jaski, Sonia Razmjou, Alireza Habibzadeh, Ahmad Maleki Ahmadabadi, Babak Gholamine, Mahdi Behi, Zahra Tavassoli

    Introduction: Sodium-glucose transporter 2 (SGLT-2) inhibitors induce glycosuria. Therefore, using a meta-analysis study, this study aimed to evaluate the correlation between SGLT2 inhibitor administration and urinary tract infection (UTI) risk. Materials and Methods: In this systematic review and meta-analysis, we conducted searches on Scopus, PubMed, Web of Science, Cochrane, and Google Scholar without time limitations up to October 16, 2023. Data were analyzed using STATA 14 software, and a significance level of P < 0.05 was considered. Results: The combination of 11 studies revealed that the use of SGLT2 inhibitors, when compared to glucagon-like peptide-1 (GLP-1) receptor agonists, reduced the risk of UTI (OR = 0.77; 95% CI: 0.62, 0.95) and when compared to insulin (OR = 0.74; 95% CI: 0.63, 0.87). However, the administration of SGLT2 inhibitors, when compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors (OR = 1.09; 95% CI: 0.90, 1.32), sulfonylureas (OR = 1.35; 95% CI: 0.88, 2.05), biguanide initiators (OR = 1.14; 95% CI: 1.05, 1.24), thiazolidinediones (OR = 1.19; 95% CI: 0.58, 2.44), and other antidiabetic drugs (OR = 1.20; 95% CI: 0.92, 1.57), did not increase the risk of UTI. The administration of dapagliflozin (OR = 1.51; 95% CI: 0.60, 3.81), canagliflozin (OR = 1.22; 95% CI: 0.47, 3.15), and empagliflozin (OR = 3.22; 95% CI: 2.97, 3.48) showed associations with UTI risk. Furthermore, the correlation between SGLT2 inhibitors use and UTI risk was observed in cohort studies (OR = 1.14; 95% CI: 0.98, 1.32), cross-sectional studies (OR = 0.86; 95% CI: 0.64, 1.14), in males (OR = 1; 95% CI: 0.72, 1.40), and females (OR = 1.17; 95% CI: 0.91, 1.52). Conclusion: Empagliflozin, in contrast to dapagliflozin and canagliflozin, increases the risk of UTI. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023479548) and Research Registry (UIN: reviewregistry1742) Websites